Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kymera Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Kymera Therapeutics, Inc.

KYMR

Kymera Therapeutics, Inc.

About Kymera Therapeutics, Inc.

Kymera Therapeutics is a biopharmaceutical company focused on developing targeted protein degradation therapies for immune-inflammatory diseases. Its pipeline includes oral small molecules targeting STAT6, TYK2, and IRAK4, aiming to treat conditions like atopic dermatitis, asthma, and hidradenitis suppurativa. The company leverages innovative degradation technology to create highly selective, potentially first-in-class medicines with advantages over biologics, targeting high unmet medical needs globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kymera Therapeutics, Inc.

1
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports $34.4M Collaboration Revenue and $69.2M Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports $311.4 Million Net Loss and Increased R&D Expenses for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports $82.2 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports Q2 2025 Financial Results, Collaboration Revenue Declines

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports $22.1M Collaboration Revenue and $65.6M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kymera Therapeutics, Inc. Kymera Therapeutics Reports Financial Results, Increases Marketable Securities and Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments